Brief: Jhbp Cy Says NMPA Grants New Approval For Phase I/Ii Clinical Trials Of Gb261 (Cd20/Cd3 Bsab)
24/05/2022 13:34
May 24 (Reuters) - Genor Biopharma Holdings Ltd 6998.HK :
* NMPA GRANTS NEW APPROVAL FOR PHASE I/II CLINICAL TRIALS OF
GB261
(CD20/CD3 BSAB)
Source text for Eikon: ID:nHKS8hbqWJ
Further company coverage: 6998.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Edding Genor group
See all newsBrief: Edding Genor Says CEO Initiates Plan To Purchase Additional Shares In Open Market
Brief: Edding Genor Posts Net Profit Increased To Rmb399.3 Million In 2025
Brief: Genor Biopharma Says NMPA Granted New Drug Application Approval For Lerociclib (Gb491)
Brief: Genor Biopharma, Its Unit & Edding Group Entered Into Merger Agreement
Brief: Genor Biopharma Says Guo Feng Tendered His Resignation As Chairman